Endothelin in cerebrospinal fluid and plasma of patients in the early stage of ischemic stroke.
- 1 October 1997
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 28 (10) , 1951-1955
- https://doi.org/10.1161/01.str.28.10.1951
Abstract
Background and Purpose Endothelin 1 (ET-1), a highly potent endogenous vasoactive peptide, exerts a sustained vasoconstrictive effect on cerebral vessels. Elevation of ET-1 in plasma has been reported 1 to 3 days after ischemic stroke. Since we assumed that a much faster and more intense response may be observed in the cerebrospinal fluid (CSF) and since an increase in concentration of ET-1 in the CSF may cause constriction of cerebral vessels and eventually influence the neurological outcome, we measured ET-1 values in the CSF within 18 hours of stroke onset and compared the values with those in the plasma. Methods Twenty-six consecutive patients with acute stroke were clinically evaluated according to the modified Matthew Scale and underwent two repeat CT scans. Within 5 to 18 hours of stroke onset, lumbar puncture and blood samples were concomitantly obtained and tested; ET-1 levels in CSF and plasma of these patients were analyzed by radioimmunoassay and compared with the levels of a control group of patients with no neurological disease. Results The mean CSF concentration of ET-1 in the CSF of stroke patients was 16.06±4.9 pg/mL, compared with 5.51±1.47 pg/mL in the control group ( P <.001). It was significantly higher in cortical infarcts (mean, 17.7±4.1 pg/mL) than in subcortical lesions (mean, 10.77±4.1 pg/mL) ( P <.001) and significantly correlated with the volume of the lesion ( P =.003). The correlation between ET-1 levels in the CSF and the Matthew Scale score was less significant ( P =.05). Plasma ET-1 level was not elevated in any group. Conclusions ET-1 is found to be significantly elevated in the CSF of stroke patients during the 18 hours after stroke. No elevation was demonstrated in plasma at this time period. ET-1 may be used as an additional indicator of ischemic vascular events in the early diagnosis of stroke. The dissimilarity between the CSF and plasma ET-1 concentrations may lead also to an hypothesis that there is a vasoconstrictive effect on the cerebral vessels or a neuronal effect caused by ET-1 in the mechanism of the progression of brain ischemia.Keywords
This publication has 24 references indexed in Scilit:
- Endothelin receptor subtypes and their role in transmembrane signaling mechanismsPharmacology & Therapeutics, 1995
- FR139317, a specific ETA-receptor antagonist, inhibits cerebral activation by intraventricular endothelin-1 in conscious ratsNeuropharmacology, 1994
- Cerebral microvascular responses to endothelins: the role of ETA receptorsBrain Research, 1994
- Anti-ischaemic efficacy of a nitric oxide synthase inhibitor and a N-methyl-d-aspartate receptor antagonist in models of transient and permanent focal cerebral ischaemiaBritish Journal of Pharmacology, 1994
- Increased endothelin-1 in the rabbit model of middle cerebral artery occlusionNeuroscience Letters, 1994
- Endothelins and sarafotoxins: Physiological regulation, receptor subtypes and transmembrane signalingPharmacology & Therapeutics, 1992
- Effect of Endothelin on the Canine Basilar ArteryNeurosurgery, 1990
- Effects of endothelin on blood vessels of the brain and choroid plexusBrain Research, 1990
- Endothelin and the production of cerebral vasospasm in dogsBiochemical and Biophysical Research Communications, 1989
- Vasoconstrictor response of large cerebral arteries of cats to endothelin, an endothelium-derived vasoactive peptideEuropean Journal of Pharmacology, 1989